The abstract is read at the publisher; the summary is JClub's.
Clomipramine shows the largest estimated short-term efficacy for obsessive-compulsive disorder in adults, but it is less tolerable than placebo and most SSRIs.
- Why it matters: Clinicians have multiple medication options, yet comparative efficacy and tolerability across ages are unclear, limiting evidence-based shared decision-making for acute treatment.
- What they did: A systematic review and network meta-analysis of 52 double-blind randomized controlled trials (7316 participants) compared licensed pharmacological treatments over 8–16 weeks, separately for children/adolescents (N=822) and adults (N=6494).
- The result: In adults, clomipramine improved symptoms versus placebo (SMD -0·71, 95% CI -0·88 to -0·54; high) but had worse tolerability (OR 4·65, 95% CI 3·27 to 6·60; moderate), with superiority over fluoxetine (SMD -0·34, -0·65 to -0·04; low).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.